论文部分内容阅读
用免疫组化方法，观察乳腺癌及良性病变是否有Bcl－2表达；Bcl－2表达及丧失与激素受体的相关性；Bcl－2表达与肿瘤分级的关系等。结果发现Bcl－2表达与ER、PR、肿瘤组织分级显著相关，Bcl－2表达阳性的乳腺癌多伴有ER＋（75％）、PR＋（70％），而Bcl－2阴性表达与预后较差的分子标志呈正相关，即ER、PR阴性率高、组织分级高。我们的发现支持了乳腺癌Bcl-2表达受激素调节的假说。
Immunohistochemistry was used to observe the expression of Bcl-2 in breast cancer and benign lesions, and the relationship between Bcl-2 expression and loss and hormone receptors, and the relationship between Bcl-2 expression and tumor grade. The results showed that Bcl-2 expression was significantly associated with ER, PR, and tumor grade. Bcl-2 positive breast cancer was often associated with ER+ (75%) and PR+ (70%). Bcl-2 negative expression was associated with poor prognosis. The molecular markers are positively correlated, ie, high ER and PR negative rates and high tissue grading. Our findings support the hypothesis that Bcl-2 expression is regulated by hormones in breast cancer.